<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895945</url>
  </required_header>
  <id_info>
    <org_study_id>241502</org_study_id>
    <nct_id>NCT02895945</nct_id>
  </id_info>
  <brief_title>BAX 802 in CHA With Inhibitors</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects With Congenital Hemophilia A With Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of BAX 802 in males with
      congenital hemophilia A (CHA) with inhibitors who are undergoing major or minor elective
      surgical, dental, or other invasive procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2016</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Hemostatic Efficacy Assessment score (GHEA)- composed of 3 individual ratings</measure>
    <time_frame>Day 0, Day 1, and postoperative (postop) day 14 or discharge (whichever is earlier)</time_frame>
    <description>GHEA=Sum of 1-3 ratings. Excellent: 7-9 (no category &lt;2) Good: 5-7 (no category &lt;1) Fair: 3-4 (no category &lt;1) None 0-2 (≥ category 0). a. Intra operative hemostatic efficacy (Excellent=3: Good=2: Fair=1: None =0). b. Hemostatic efficacy postoperative Day 1 (Excellent=3: Good=2: Fair=1: None =0). c. Overall perioperative hemostatic efficacy at discharge or ≤ day 14 (Excellent=3: Good=2: Fair=1: None =0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss compared to the estimated volume of expected average blood in a comparable healthy individual</measure>
    <time_frame>End of surgery; approximately 24 hours after surgery; and Day 14 or discharge (whichever is earlier)</time_frame>
    <description>Predicted preoperatively by the investigator/surgeon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss compared to the estimated volume of expected maximum blood loss in a comparable healthy individual</measure>
    <time_frame>End of surgery; approximately 24 hours after surgery; and Day 14 or discharge (whichever is earlier)</time_frame>
    <description>Predicted preoperatively by the investigator/surgeon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of bleeding episodes</measure>
    <time_frame>Day 0 (day of surgery) thru Day 14 or discharge (whichever is earlier)</time_frame>
    <description>During the intra- and postoperative periods and additional need for surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment of unrelated bleeding episodes in the postoperative period</measure>
    <time_frame>Day 0 (postoperative) thru Day 14 or discharge (whichever is earlier)</time_frame>
    <description>Rating Scale for Treatment of Unrelated BEs (4-point ordinal scale): • Excellent: Full relief of pain and cessation of objective signs of bleeding after a single infusion. No additional infusion required for the control of bleeding. Administration of further infusions to maintain hemostasis would not affect this scoring. • Good: Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution. • Fair: Probable and/or slight relief of pain and slight improvement in signs of bleeding after single infusion. Required more than 1 infusion for complete resolution. • None: No improvement or condition worsens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of, and changes to, the titer of inhibitory and binding antibodies to recombinant porcine factor VIII (rpFVIII)</measure>
    <time_frame>≤45 days prior to Day 0; postoperative day 14 or discharge (whichever is earlier); optional testing between day 7- 14 after discharge; and day 42 after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of, and changes to, the titer of inhibitory and binding antibodies to human factor VIII (hFVIII)</measure>
    <time_frame>≤45 days prior to Day 0; postoperative day 14 or discharge (whichever is earlier); optional testing between day 7- 14 after discharge; and day 42 after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of binding antibodies to baby hamster kidney (BHK) proteins</measure>
    <time_frame>≤45 days prior to Day 0; postoperative day 14 or discharge (whichever is earlier); optional testing between day 7- 14 after discharge; and day 42 after discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of thrombotic events</measure>
    <time_frame>After signing informed consent until day 42 after discharge (end of study visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe allergic reactions (eg, anaphylaxis)</measure>
    <time_frame>From Day 0 (day of surgery) through Day 42 post-surgery (End of Study Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of other investigational product (IP)-related adverse events (AEs)</measure>
    <time_frame>From Day 0 (day of surgery) through Day 42 post-surgery (End of Study Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs</measure>
    <time_frame>Within 30 minutes pre, and 30 minutes post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in routine laboratory parameters - hematology labs</measure>
    <time_frame>Up to 45 days prior to Day 0 (day of surgery) through Day 42 post-surgery (End of Study Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in routine laboratory parameters - clinical chemistry</measure>
    <time_frame>Up to 45 days prior to Day 0 (day of surgery) through Day 42 post-surgery (End of Study Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily administration of BAX 802 per participant</measure>
    <time_frame>Day 0 (day of surgery) thru Day 14 or discharge (whichever is earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total weight-adjusted administration of BAX 802 per participant</measure>
    <time_frame>Day 0 (day of surgery) thru Day 14 or discharge (whichever is earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume (mL) of Blood Products Transfused.</measure>
    <time_frame>From initiation of the surgery until Day 14 or discharge (whichever is earlier)</time_frame>
    <description>Volume of blood transfused may include: blood, red blood cells, platelets, and other blood products transfused</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>BAX802 in Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)</intervention_name>
    <description>In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.</description>
    <arm_group_label>BAX802 in Surgery</arm_group_label>
    <other_name>BAX 802</other_name>
    <other_name>BAX802</other_name>
    <other_name>recombinant porcine factor VIII</other_name>
    <other_name>Obizur</other_name>
    <other_name>rpFVIII</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant is ≥ 18 to ≤ 65 years old at the time of screening

          2. Participant has provided signed informed consent

          3. Participant has severe (Factor VIII (FVIII) level &lt; 1%) or moderately severe (FVIII
             level ≤ 2%) Congenital Hemophilia A (CHA) with inhibitors to human FVIII, as tested at
             screening at the central laboratory

          4. Participant requires elective surgery or other invasive procedures

          5. Participant is not currently receiving or has received (&lt; 30 days) immune tolerance
             induction (ITI) therapy

          6. Participant has a Karnofsky performance score of ≥ 60

          7. Participant is human immunodeficiency virus negative (HIV-); or HIV+ with stable
             disease and CD4+ count ≥ 200 cells/mm^3 at screening

          8. Participant is hepatitis C virus negative (HCV-) by antibody or polymerase chain
             reaction (PCR) testing; or HCV+ with chronic stable hepatitis disease

          9. Participant is willing and able to comply with the requirements of the protocol.

        Exclusion Criteria:

          1. The participant requires emergency surgery

          2. The participant's weight is &lt; 35 kg or &gt; 120 kg

          3. Clinically symptomatic liver disease (eg, ≥ 5 X upper limit of normal alanine
             aminotransferase [ALT], as confirmed by central laboratory at screening, clinical
             evidence of portal hypertension, severe hypoalbuminemia or a documented prothrombin
             time/international normalized ratio (PT/INR) &gt; 1.5)

          4. Clinically symptomatic renal disease (serum creatinine &gt; 2.0 mg/dL), as confirmed by
             central laboratory at screening

          5. Anti-porcine inhibitor &gt; 10 BU prior to surgery

          6. Platelet count &lt; 100,000/μL

          7. Participant has another active coagulation disorder other than hemophilia A, as per
             the medical history Planned use of α-interferon with or without ribavarin for HCV
             infected patients or planned use of a protease inhibitor for HIV infected patients.
             Patients currently taking any of these medications for ≥ 30 days are eligible

        9. Known hypersensitivity to recombinant porcine factor VIII (rpFVIII), or hamster or
        murine proteins 10. Participant has been exposed to an investigational product (IP) within
        30 days prior to enrollment or is scheduled to participate in another clinical study
        involving an IP or investigational device during the course of this study 11. Unable to
        tolerate quantity of blood to be drawn for protocol procedures 12. Participant is a family
        member or employee of the investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shouryadeep Srivastava, MBBS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta now part of Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Krammer, MSc</last_name>
    <phone>+43 1 20100 247 1372</phone>
    <email>michael.krammer@shire.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salvador Dominguez</last_name>
    <email>Salvador.Dominguez@shire.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bleeding and Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont d/b/a CIUSSS de l'Est-de-l'Île-de-Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico-1-AMF7BT</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht-1-1YA-3214</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii-1-1Y7-1347</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña-1-2WKDXY</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz-1-IKVQAW</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Thomas' Hospital-1-M6DQZK</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary-1-1PA3SZ</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

